Fallopian Tube Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma that arises from the fallopian tube. Histologic subtypes include clear cell, endometrioid, serous, and mucinous adenocarcinoma. It spreads to adjacent organs, regional lymph nodes, and peritoneum. 
Fallopian tube adenocarcinomas most frequently harbor alterations in TP53, NOTCH3, CCNE1, BRD4, and SMARCA4 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 8 Mutation, and TP53fs are the most common alterations in fallopian tube adenocarcinoma .
There are 10 clinical trials for fallopian tube adenocarcinoma, of which 7 are open and 3 are completed or closed. Of the trials that contain fallopian tube adenocarcinoma as an inclusion criterion, 3 are phase 1 (2 open), 5 are phase 1/phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).
BRCA1 and BRCA2 are the most frequent gene inclusion criteria for fallopian tube adenocarcinoma clinical trials .
Carboplatin, paclitaxel, and anlotinib are the most common interventions in fallopian tube adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.